Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
High selectivity for MC4R significantly reduces potential for skin pigmentationMC4R is a well-validated target for treating obesityClinical studies with highly selective MC4R agonists targeted to commence in calendar year 2025